Abstract
dc:description”Patients in rare diseases should be entitled to the same quality of treatment as other patients”. The recent implementation of international and national strategy plans for rare diseases has led to an incredible increase of data quantity. As is generally known, such data become available through various sources, for instance; claim databases, e-health records, national registries and experimental studies. Information provided from either of these sources can be utilized during the evaluation of a (new) treatment. Depending on the stakeholder, we often need to evaluate multiple questions; such as, (i) do the treatment’s risks outweigh the added benefit?, (ii) does the treatment’s added benefit outweigh the costs?, (iii) does the treatment help each and every individual patient or (iv) does the treatment actually work? The latter question is often evaluated by a randomized controlled trial. According to Orphanet, more than 1829 trials among 29 countries focus on more than 800 rare conditions. This number of historical and ongoing trials explains the urgent need for evaluating and developing tailor-made statistical methods for small populations and so far, three recent large European projects have responded to materializing this need. Statisticians, methodologists, clinicians and patients, all interested parties recognize the specific issue of the increased presence of heterogeneity among the patients that suffer from a specific rare condition. Heterogeneity introduces further complexity during the evaluation of a (new) treatment within a single randomized clinical trial, where the limited availability of sample sizes restricts practitioners from evaluating subgroups of patients within each trial. Although counter-intuitive, as sample sizes per trial become smaller, conducting more than one trial might provide a clearer overview of the treatment efficacy. Orphan drugs for rare diseases are often investigated through multinational randomized controlled trials. Investigations in such a global setting may lead to increased inconsistency, given that the clinical expertise, the standards of care and the used facilities vary e.g. between each country. Non-homogeneous data makes single trials less reliable, which means that the need to explore synthesis methods of a few small studies through meta-analysis is even more necessary. This thesis focuses on the latter.
Degree
thesis:*- Grantor dc:publisher
- Institutes outside Greece
- Year dc:date
- 2020
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Pateras, Konstantinos
- Πατέρας, Κωνσταντίνος
Subjects
dc:subject × 27- Σπάνια νοσήματα
- Ετερογένεια
- Μετα-ανάλυση
- Μετα-ανάλυση δικτύου
- Σύνθεση πληροφορίας
- Μπευζιανή συμπερασματολογία
- Προσομοίωση
- Χαμένα δεδομένα
- Σπάνια γεγονότα
- Rare diseases
- Small populations
- Heterogeneity
- Meta-analysis
- Network meta-analysis
- Evidence synthesis
- Bayesian
- Simulation
- Missing outcome data
- Rare events
- Μαθηματικά
- Φυσικές Επιστήμες
- Στατιστική και Πιθανότητες
- Άλλες Φυσικές Επιστήμες
- Mathematics
- Natural Sciences
- Statistics and Probability
- Other Natural Sciences
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/52102